Delivery Order SPE2DB24D2101-SPE2DB25FKNCX
- Not listed
- The Defense Logistics Agency awarded a $14,221.60 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a specialized oncology medication, with performance at the contractor's Conshohocken, Pennsylvania location. The contract is structured as a firm fixed-price delivery order under a non-competitive set-aside, with an ultimate completion date of October 3, 2025. This award represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 16, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a specialty pharmaceutical product, with a ceiling value of $7,110.80. This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 29, 2025. The award leverages AmerisourceBergen's established Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global...
- The Defense Logistics Agency awarded a $10,666.20 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a oncology therapeutic agent, with performance in Conshohocken, Pennsylvania and completion targeted for June 13, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,443.90 for 100 mg vials of Enhertu, a oncology therapeutic agent, with performance in Conshohocken, Pennsylvania and completion scheduled for May 13, 2025. This competitively awarded, firm fixed-price delivery order contains no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply framework with the federal government. This delivery order executes...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $7,110.80 by the Defense Logistics Agency for 100 milligram vials of Enhertu, a prescription oncology medication. The contract, awarded on August 26, 2025, with completion targeted for September 17, 2025, is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Enhertu 100 mg vials, valued at $8,888.50 with a firm fixed price arrangement. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a $17,777.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a oncology therapeutic medication used in cancer treatment. The contract was competitively awarded without a set-aside designation and is scheduled for completion by October 8, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime...
- The Defense Logistics Agency awarded a $7,110.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Enhertu 100 mg vials, with an ultimate completion date of September 24, 2025. This non-set-aside award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery location is AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Enhertu 100 mg vials valued at $10,666.20 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The award involved no set-aside designation, indicating competitive...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNCXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,221.60 to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a specialty oncology medication, with performance in Conshohocken, Pennsylvania. This firm fixed-price delivery order, awarded on August 6, 2025, was competitively awarded without set-aside designation and is scheduled for completion by August 27, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) SPE2DX with DLA Troop Support Medical, valued at approximately $1 billion and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. This delivery order for Enhertu supports the company's comprehensive role under the broader pharmaceutical prime vendor agreement, which enables distribution of specialized medications across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 8/6/25 |